CMET-22. INTRATHECAL (IT) TRAZTUZUMAB (T) FOR THE TREATMENT OF LEPTOMENINGEAL METASTASES (LM) IN PATIENTS (PTS) WITH HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-POSITIVE (HER2+) CANCER: A MULTICENTER PHASE 1/2 STUDY

Pts with HER2+ breast cancer have frequent LM. No current FDA approvals exist. A multicenter phase I/II trial assessing safety and efficacy of IT T in LM pts was conducted. The primary endpoint in phase 2 was response rate (RR). Complete response (CR) required cytologic CR (CCR) + radiographic CR (R...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neuro Oncol
Main Authors: Kumthekar, Priya, Gradishar, William, Lin, Nancy, Pentsova, Elena, Groves, Morris, Jeyapalan, Suriya, Melisko, Michelle, Grimm, Sean, B. Lassman, Andrew, Raizer, Jeffrey
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2018
Assuntos:
Abstracts
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6216912/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy148.234
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados